Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 11/20 | 0.45 |
| ▸ | FABP4 | P15090 | 3/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24928646 | 1.00 | ACLY (0.45) | ACLYFABP4FABP5PTK2BSMN1; SMN2 | |
| SCHEMBL24928654 | 0.90 | ACLY (0.37) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL31198454 | 0.90 | ACLY (0.37) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL24928715 | 0.89 | ACLY (0.37) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL30153301 | 0.89 | ACLY (0.37) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL24928649 | 0.86 | ACLY (0.41) | ACLYFABP4FABP5ERAP1TDP1 | |
| SCHEMBL30153363 | 0.86 | ACLY (0.41) | ACLYFABP4FABP5ERAP1TDP1 | |
| SCHEMBL30153205 | 0.83 | ACLY (0.35) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL24928721 | 0.83 | ACLY (0.35) | ACLYFABP4PTK2BSMN1; SMN2TDP1 | |
| SCHEMBL22637065 | 0.81 | ACLY (0.41) | ACLYPTK2BSMN1; SMN2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376046-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376046-A1 | PHENYL-SULFAMOYL-BENZOIC ACID DERIVATIVES AS ERAP1- MODULATORS | ERAP1, XPO1, RRP15 | ACLY 3207/4885FABP4 4730/4885FABP5 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.